Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada Chronic Disease epidemiology

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Blanc Lapierre, Audrey ^a   Spence, Andrea ^a   Karakiewicz, Pierre I ^b   Aprikian, Armen ^c   Saad, Fred ^b   Parent, Marie Élise ^a,d  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Case control studies; Epidemiology; Metabolic syndrome; Prostate cancer; Risk factors

Indexed keywords

ADULT; AGED; CASE CONTROL STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; ODDS RATIO; ONSET AGE; PREVALENCE; PROSTATIC NEOPLASMS; QUEBEC; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGE OF ONSET; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; ODDS RATIO; PREVALENCE; PROSTATIC NEOPLASMS; QUEBEC; RISK FACTORS;

EID: 84942088307     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-2260-x     Document Type: Article

References (61)

1. Globocan 2012 [ http://globocan.iarc.fr/ ].
2. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci J Virtual Libr. 2006;11:1388-413.
3. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst. 1968;40:43-68.
4. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care. 2004;27:2444-9.
5. Platz EA, Giovannucci E: Prostate cancer. In Cancer epidemiology and prevention. 3rd edition. Eastbourne, UK; W.B. Saunders Co; 2006;59:1128-50.
6. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48.
7. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
8. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33:351-75. table of contents.
9. Ervin RB: Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Rep 2009;13:1-7.
10. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-70.
11. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2010;12:e157-80.
12. Chu DI, Freedland SJ. Metabolic Risk Factors in Prostate Cancer. Cancer. 2011;117:2020-3.
13. Grossmann M, Wittert G. Androgens, diabetes and prostate cancer. Endocr Relat Cancer. 2012;19:F47-62.
14. Hsing AW, Sakoda LC, Chua Jr S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86:s843-57.
15. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer - a dose-response meta-analysis of prospective studies. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23:1665-71.
16. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control CCC. 2006;17:989-1003.
17. Allott EH, Masko EM, Freedland SJ. Obesity and Prostate Cancer: Weighing the Evidence. Eur Urol. 2013;63:800-9.
18. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev. 2007;29:88-97.
19. Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 2013;104:9-14.
20. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16:151-8. S1.
21. De Nunzio C, Tubaro A. Prostate cancer: Diabetes and prostate cancer - an open debate. Nat Rev Urol. 2013;10:12-4.
22. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, et al. Effect of metabolic syndrome and its components on prostate cancer risk: Meta-analysis. J Endocrinol Invest. 2013;36:132-9.
23. Xiang Y-Z, Xiong H, Cui Z-L, Jiang S-B, Xia Q-H, Zhao Y, et al. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res CR. 2013;32:9.
24. Blanc-Lapierre A, Weiss D, Parent M-É. Use of oral anticoagulants and risk of prostate cancer: a population-based case-control study in Montreal, Canada. Cancer Causes Control CCC. 2014;25:1159-66.
25. Spence AR, Rousseau M-C, Karakiewicz PI, Parent M-É. Circumcision and prostate cancer: a population-based case-control study in Montréal. BJU Int: Canada; 2014.
26. Yu J, Lavoué J, Parent M-É. Sunlight exposure during leisure activities and risk of prostate cancer in Montréal, Canada, 2005-2009. BMC Public Health. 2014;14:756.
27. Parent M-É, Goldberg MS, Crouse DL, Ross NA, Chen H, Valois M-F, et al. Traffic-related air pollution and prostate cancer risk: a case-control study in Montreal, Canada. Occup Environ Med. 2013;70:511-8.
28. Parikh RM, Joshi SR, Pandia K. Index of central obesity is better than waist circumference in defining metabolic syndrome. Metab Syndr Relat Disord. 2009;7:525-7.
29. Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4∈+∈3 and Gleason 3∈+∈4 tumors in a population based cohort. J Urol. 2009;182:2702-7.
30. Choi H-C, Park J-H, Cho B-L, Son K-Y, Yoo Y-J, Kwon H-T. The illusion of prostate-specific antigen decline in patients with metabolic syndrome and insulin resistance. BJU Int. 2011;108:1756-61.
31. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA J Am Med Assoc. 2007;298:2275-80.
32. Chu DI, De Nunzio C, Gerber L, Thomas 2nd J-A, Calloway EE, Albisinni S, et al. Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer Prostatic Dis. 2011;14:346-53.
33. Riediger ND, Clara I. Prevalence of metabolic syndrome in the Canadian adult population. CMAJ Can Med Assoc J J Assoc Medicale Can. 2011;183:E1127-34.
34. Metabolic syndrome in Canadians, 2009 to 2011 [ http://www.statcan.gc.ca/pub/82-625-x/2012001/article/11735-eng.htm ].
35. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA J Am Med Assoc. 2002;288:2709-16.
36. Lawrence YR, Morag O, Benderly M, Boyko V, Novikov I, Dicker AP, et al. Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer Prostatic Dis. 2013;16:181-6.
37. Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N, et al. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer. 2011;117:2086-95.
38. Häggström C, Stocks T, Nagel G, Manjer J, Bjørge T, Hallmans G, et al. Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiol Camb Mass. 2014;25:823-8.
39. Bansal D, Undela K, D'Cruz S, Schifano F. Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. PLoS One. 2012;7.
40. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D, et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology. 2009;74:185-90.
41. Lund Håheim L, Wisløff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006;164:769-74.
42. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2010;19:2088-96.
43. Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol. 2011;21:835-41.
44. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2004;13:1646-50.
45. Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, et al. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int. 2011;107:929-35.
46. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006;164:1094-102.
47. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer. 2007;109:875-81.
48. Yates D, Anderson J: Screening for Prostate Cancer. In Prostate Cancer: A Comprehensive Perspective. Tewari, A. London: Springer; 2013;2:333-346.
49. Häggström C, Stocks T, Ulmert D, Bjørge T, Ulmer H, Hallmans G, et al. Prospective study on metabolic factors and risk of prostate cancer. Cancer. 2012;118:6199-206.
50. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A, et al. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate. 2011.
51. Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, et al. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int. 2013;111:1031-6.
52. Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, et al. Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. Eur Urol. 2014.
53. Sourbeer KN, Howard LE, Andriole GL, Moreira DM, Castro-Santamaria R, Freedland SJ, et al. Metabolic syndrome-like components and prostate cancer risk: Results from the REDUCE Study. BJU Int. 2014.
54. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TIL. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control CCC. 2009;20:1181-92.
55. Osaki Y, Taniguchi S, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol. 2012;36:141-7.
56. Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C, et al. Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetol. 2012;49 Suppl 1:S235-46.
57. Krycer JR, Brown AJ. Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective. Biochim Biophys Acta. 1835;2013:219-29.
58. Morote J, Celma A, Planas J, Placer J, de Torres I, Olivan M, et al. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int J Mol Sci. 2014;15:13615-23.
59. Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT. High-density lipoprotein and prostate cancer: an overview. J Epidemiol Jpn Epidemiol Assoc. 2013;23:313-9.
60. Pelton K, Freeman MR, Solomon KR. Cholesterol and prostate cancer. Curr Opin Pharmacol. 2012;12:751-9.
61. Solomon KR, Freeman MR. The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am. 2011;38:243-59.